Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 0.46 |
| ▸ | FNTB | P49356 | 15/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 14/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7632596 | 0.92 | FNTA (0.48) | FNTAFNTBPGGT1BMEN1MAPK1 | |
| SCHEMBL7624853 | 0.90 | FNTA (0.47) | FNTAFNTBPGGT1BMEN1MAPK1 | |
| SCHEMBL7622896 | 0.90 | FNTA (0.47) | FNTAFNTBPGGT1BMEN1MAPK1 | |
| SCHEMBL7626193 | 0.87 | FNTA (0.47) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL7622644 | 0.86 | FNTA (0.47) | FNTAFNTBPGGT1BMEN1MAPK1 | |
| SCHEMBL7622752 | 0.86 | FNTA (0.47) | FNTAFNTBPGGT1BMEN1MAPK1 | |
| SCHEMBL7621675 | 0.85 | FNTA (0.46) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL7623128 | 0.85 | FNTA (0.46) | FNTAFNTBPGGT1BMEN1MAPK1 | |
| SCHEMBL7628927 | 0.83 | FNTA (0.46) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL7622383 | 0.83 | FNTA (0.49) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052363-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-05-02 | — | — | US | claimed |
| WO-2001060369-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | claimed |
| US-20020052363-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2001060369-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052363-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, PTAR1 | FNTA 1/4885FNTB 2/4885PGGT1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.